Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors

Bone Marrow Transplantation

Volumn 22, Issue 6, 1998, Pages 535-540

  Lucidarme, N ^a   Valteau Couanet, D ^a   Oberlin, O ^a   Couanet, D ^a   Kalifa, C ^a   Beaujean, F ^b   Lapierre, V ^a   Hartmann, O ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CTS   (France)

Author keywords

Hematopoietic stem cell transplantation; High dose thiotepa; Pediatric solid tumors

Indexed keywords

ALKYLATING AGENT; THIOTEPA;

ADOLESCENT; ARTICLE; BURKITT LYMPHOMA; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DRUG MEGADOSE; EWING SARCOMA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; METASTASIS; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SEPTICEMIA; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0031669507     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701395     Document Type: Article

References (34)

1. Saarinen UM, Hovi L, Mäkipernaa A, Riikonen P. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant 1991; 8: 369-376.
2. Wolff SN, Herzig RH, Fay JW et al. High-dose N,N',N"-triethylthiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 1990; 17 (Suppl. 3): 2-6.
3. Herzig RH, Brown RA, Fay JW et al. Phase I and II studies of high dose N,N',N"-triethylene thiophosphoramide and autologous marrow transplantation in patients with refractory malignancies. Cancer The and Control 1990; 1: 141-153.
4. Samuels BL, Bitran JD. High-dose intravenous Melphalan: a review. J Clin Oncol 1995; 13: 1786-1799.
5. O' Dwyer PJ, LaCreta F, Engstrom PF et al. Phase I: pharmacokinetic reevaluation of thioTEPA. Cancer Res 1991; 51: 3171-3176.
6. Strandjord S, Saarinen U, Warkentin P et al. High-dose N,N',N"-triethylenethiophosphoramide in pediatrie phase I-II autologous bone marrow transplantation studies. Exp Hematol 1988; 16: 503 (Abstr. 176).
7. Kalifa C, Hartmann O, Demeocq F et al. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant 1992; 9: 227-233.
8. Heideman RL, Packer RJ, Reaman GH et al. A phase II evalu- ation of thiotepa in pediatric central nervous system malig- nancies. Cancer 1993; 72: 271-275.
9. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
10. Avril M, Hartmann O, Valteau-Couanet et al. Anti-infective prophylaxis with ceftazidine and teicoplanin in children undergoing high-dose chemotherapy and bone-marrow transplantation. Pediatr Hematol Oncol 1994; 11: 63-73.
11. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone-marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
12. O'Dwyer PJ, LaCreta FP, Schilder R et al. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 1352-1358.
13. Hartmann O, Kalifa C, Benhamou E et al. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol 1986; 16: 165-169.
14. Maraninchi D, Pico JL, Hartmann O et al. High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and or relapsed acute leukemias. Cancer Treat Rep 1986; 70: 445-148.
15. Frei E, Canellos GD. Dose: a critical factor in cancer chemotherapy. Am J Med 1979; 69: 585-594.
16. Heideman RL, Cole DE, Balis F et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736-741.
17. Tabone MD, Kalifa C, Rodary C et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994; 12: 2614-2620.
18. Ladenstein R, Hartmann O, Pinkerton CR. The role of mega-therapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol 1993; 4 (Suppl. 1): 45-58.
19. Crist WM, Garnsey L, Beltangady MS et al. Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. J Clin Oncol 1990; 8: 443-452.
20. Koscielniak E, Rodary C, Flamant F et al. Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. Med Fed Oncol 1992; 20: 209-214.
21. Ladenstein R, Lasset L, Pinkerton R et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT solid tumour registry. Bone Marrow Transplant 1995; 15: 697-705.
22. Pinkerton CR, Ladenstein R, Chauvin F. Megatherapy with autologous bone marrow rescue in advanced rhabdomyosarcoma. The EBMT Group Experience. EBMT XVIII Meeting. EBMT 1992; 160 (Abstr. 225).
23. Valteau-Couanet D, Vassal G, Pautard G et al. Feasibility of repeated high-dose VP16 continuous intraveinous infusion in children. Proc ASCO 1995; 448 (Abstr. 1433).
24. Hartmann O, Oberlin O, Beaujean F et al. Place de la chimiothérapie à hautes doses suivie d'autogreffe médullaire dans le traitement des sarcomes d'Ewing métastatiques de l'enfant. Bull Cancer 1990; 77: 181-187.
25. Michon J, Oberlin O, Demeocq F et al. Poor results in meta- static Ewing's sarcoma treated according to the scheme of the Saint Jude 1978-1985 study: a study of the French Society of Pediatric Oncology. SIOP XXV Meeting. Med Ped Oncol 1993; 21: 572 (Abstr. 71).
26. Valteau-Couanet D, Benhamou E, Oberlin O et al. Consolidation with busulfan and melphalan followed by hematopoietic stem-cell transplantation in children with poor prognosis Ewing's sarcoma. SIOP XXVII Meeting. Med Ped Oncol 1995; 25: 312 (Abstr. p133).
27. Lazarus HM, Reed MD, Spitzer TR et al. High-dose iv thiotepa and cryopreserved autologous bone marrow transplantalion for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689-695.
28. Dupuis-Girod S, Hartmann O, Benhamou E et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurol Oncol 1996; 27: 87-98.
29. Grill J, Kalifa C, Doz F et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase II study. Pediatr Neurosurg 1996; 25: 7-12.
30. Finlay J, August C, Packer R et al. High-dose multi-agent chemotherapy followed by bone marrow rescue for malignant astrocytomas of childhood and adolescence. J Neurol Oncol 1990; 9: 239-248.
31. Brochstein JA, Pecora AL, Van Vliet A. HD etoposide, thiotepa and cyclophosphamide with autologous marrow support for pediatric patients with high risk solid tumors. Blood 1993; 82: 628 (Abstr. 2495).
32. Crown J, Raptis G, Vahdat L et al. Rapid adiministration of sequential high-dose cyclophosphamide, melphalan, thiotepa supported by filgrastim+ peripheral blood progenitors in patients with metastatic breast cancer: A novel and very active treatment strategy. Proc Am Soc Clin Oncol 1994; 13: 110 (Abstr. 242).
33. Vahdat L, Raptis G, Fennely D et al. Rapidly cycled courses of high-dose alkylating agents supported by filgrastirn and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1995, 1: 1267-1273.
34. Valteau-Couanet D, Vassal G, Benhamou E et al. Feasibility of repeated high dose chemotherapy followed by peripheral blood stem cell transplantation in children with poor risk medulloblastoma and neuroblastoma. EBMT XXVIII Meeting. EBMT 1997.